Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
European Journal of Cancer (Oxford, England : 1990)|August 22, 2016
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancerSonya C Tate, Valerie Andre, Nathan Enas, et al.Pharmaceutical Statistics|January 7, 2020
Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designsClaire L Smith, Zachary Thomas, Nathan Enas, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancerPasi A Jänne, Luis Paz-Ares, Yun Oh, et al.Journal of Oncology|June 9, 2009
In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission TomographyKaren E Pollok, Michael Lahn, Nathan Enas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 daysJames P Stevenson, Weijing Sun, Maryann Gallagher, et al.Pharmaceutical Statistics|August 6, 2013
Use of historical control data for assessing treatment effects in clinical trialsKert Viele, Scott Berry, Beat Neuenschwander, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancerJeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2007
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson, Brad S Kahl, Julie M Vose, et al.Pageof 1